EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Postmarketing safety of migraine prophylactic monoclonal antibodies: An EudraVigilance database analysis of eptinezumab, fremanezumab, galcanezumab, and erenumab

Victoria Nikitina iD, Greta Santi Laurini iD, Nicola Montanaro iD, Domenico Motola iD

Headache: The Journal of Head and Face Pain · 2025

DOI: 10.1111/head.14962 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Headache: The Journal of Head and Face Pain, 2025. Verfasst von Victoria Nikitina und 3 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Pharmacology, Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy. Hauptthemen laut MEDLINE: Migraine Disorders, Antibodies, Monoclonal, Humanized, Product Surveillance, Postmarketing, Antibodies, Monoclonal. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives/Background This study was undertaken to evaluate the postmarketing safety of monoclonal antibodies (mAbs) targeting the calcitonin gene‐related peptide pathway used for migraine prophylaxis through pharmacovigilance data analysis by examining suspected adverse events reported in Europe. Migraine is one of the most prevalent and debilitating neurological disorders globally. The introduction of mAbs targeting the calcitonin gene‐related peptide pathway has transformed migraine prophylaxis. However, their safety profiles in real‐world settings are not fully established, and ongoing safety monitoring is essential, as clinical trials may not capture all potential adverse drug reactions associated with new therapies.

Methods

A disproportionality analysis was carried out by analyzing postmarketing pharmacovigilance data from the EudraVigilance database, focusing on four mAbs: eptinezumab, fremanezumab, galcanezumab, and erenumab. Descriptive and statistical analyses were performed on data retrieved from the date of marketing authorization of each medicine up to June 16, 2024. The reporting odds ratio (ROR), information component, and empirical Bayes geometric mean were calculated to detect signals of disproportionate reporting comparing their safety profiles to topiramate, a standard preventive migraine treatment.

Results

A total of 14,285 reports had emerged; most of them were from females and concerned patients aged 18–64 years. The most frequently reported adverse drug reactions were primarily nonserious, aligning with literature and previously established safety profiles, such as fatigue and injection site reactions. The statistical analysis revealed 15 significant disproportionality signals: 11 for eptinezumab and four for galcanezumab. Eptinezumab highlighted potential new safety signals such as palpitations (ROR = 6.93, 95% confidence interval [CI] = 3.39–14.18), oropharyngeal pain (ROR = 7.19, 95% CI = 3.40–15.24), and erythema (ROR = 12.31, 95% CI = 4.58–33.12). These findings suggest a potential class effect, warranting further investigations and highlighting the importance of continued monitoring regarding the long‐term safety of mAbs.

Conclusion

Almost all of the most reported and statistically significant adverse events were nonserious and consistent with the existing literature. Given the chronic nature of migraine treatment, continuous pharmacovigilance monitoring is essential to ensure their constant safe use in clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Migraine DisordersAntibodies, Monoclonal, HumanizedProduct Surveillance, PostmarketingAntibodies, MonoclonalPharmacovigilanceCalcitonin Gene-Related Peptide Receptor AntagonistsHumansFemaleMaleAdultMiddle AgedYoung AdultDatabases, FactualAdolescentEuropeAged

Stichwörter der Autor:innen

anti‐calcitonin gene‐related peptide monoclonal antibodiesmigrainepharmacovigilanceprophylaxis of migrainesafety

Substanzen

Antibodies, Monoclonal, HumanizedgalcanezumaberenumabAntibodies, MonoclonalfremanezumabeptinezumabCalcitonin Gene-Related Peptide Receptor Antagonists

Autor:innen und Institutionen

  • Unit of Pharmacology, Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy.
  • Alma Mater Studiorum University of Bologna, Bologna, Italy.

ORCID-Profile: Victoria Nikitina, Greta Santi Laurini, Nicola Montanaro, Domenico Motola

Zitieren

APA

Nikitina, V., Santi Laurini, G., Montanaro, N., & Motola, D. (2025). Postmarketing safety of migraine prophylactic monoclonal antibodies: An EudraVigilance database analysis of eptinezumab, fremanezumab, galcanezumab, and erenumab. Headache: The Journal of Head and Face Pain. https://doi.org/10.1111/head.14962

Vancouver

Nikitina V, Santi Laurini G, Montanaro N, Motola D. Postmarketing safety of migraine prophylactic monoclonal antibodies: An EudraVigilance database analysis of eptinezumab, fremanezumab, galcanezumab, and erenumab. Headache: The Journal of Head and Face Pain. 2025. doi:10.1111/head.14962

BibTeX
@article{Nikitina2025,
  author = {Nikitina, Victoria and Santi Laurini, Greta and Montanaro, Nicola and Motola, Domenico},
  title = {Postmarketing safety of migraine prophylactic monoclonal antibodies: An EudraVigilance database analysis of eptinezumab, fremanezumab, galcanezumab, and erenumab},
  journal = {Headache: The Journal of Head and Face Pain},
  year = {2025},
  doi = {10.1111/head.14962}
}
Kostenlos starten →